Afatinib
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Afatinib |
| DrugBank ID | DB08916 |
| Brand Names (EU) | Giotrif |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.65% |
Approved Indication (EMA)
Giotrif as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | HER2 positive breast carcinoma | 98.65% | DL |
| 2 | multiple endocrine neoplasia | 98.48% | DL |
| 3 | progesterone-receptor negative breast cancer | 97.93% | DL |
| 4 | normal breast-like subtype of breast carcinoma | 97.89% | DL |
| 5 | progesterone-receptor positive breast cancer | 97.89% | DL |
| 6 | breast tumor luminal A or B | 97.87% | DL |
| 7 | thrombocytopenia | 97.58% | DL |
| 8 | marcothrombocytopenia with mitral valve insufficiency | 97.42% | DL |
| 9 | hereditary thrombocytopenia with normal platelets | 97.39% | DL |
| 10 | dense granule disease | 97.28% | DL |
| 11 | transient neonatal thrombocytopenia | 97.23% | DL |
| 12 | malignant catarrh | 96.84% | DL |
| 13 | infectious bovine rhinotracheitis | 96.84% | DL |
| 14 | cytomegalovirus infection | 96.67% | DL |
| 15 | amenorrhea (disease) | 96.45% | DL |
| 16 | platelet storage pool deficiency | 96.18% | DL |
| 17 | myeloid leukemia | 95.15% | DL |
| 18 | amyotrophic lateral sclerosis | 94.92% | DL |
| 19 | glaucoma | 94.88% | DL |
| 20 | amyotrohpic lateral sclerosis type 22 | 94.54% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.